Donor‐Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients. Issue 8 (23rd March 2016)

• Record Type: Journal Article
• Authors: Levitsky, J.; Kaneku, H.; Jie, C.; Walsh, R. C.; Abecassis, M.; Tambur, A. R.
• Is Part Of: American journal of transplantation. Volume 16:Issue 8(2016:Aug.)
• Page Start: 2437
• Page End: 2444
• Publication Date: 2016-03-23
• Subjects: translational research/science -- clinical research/practice -- liver transplantation/hepatology -- histocompatibility -- immunobiology -- liver transplantation: living donor -- liver allograft function/dysfunction -- rejection -- antibody biology -- alloantibody; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.13757
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : With less ischemia, improved donor selection and controlled procedures, living donor liver transplantation (LDLT) might lead to less HLA donor‐specific antibody (DSA) formation or fewer adverse outcomes than deceased donor liver transplantation (DDLT). Using the multicenter A2ALL (Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study) biorepository, we compared the incidence and outcomes of preformed and de novo DSAs between LDLT and DDLT. In total, 129 LDLT and 66 DDLT recipients were identified as having serial samples. The prevalence of preformed and de novo DSAs was not different between DDLT and LDLT recipients (p = 0.93). There was no association between patient survival and the timing (preformed vs. de novo ), class (I vs. II) and relative levels of DSA between the groups; however, preformed DSA was associated with higher graft failure only in DDLT recipients (p = 0.01). De novo DSA was associated with graft failure regardless of liver transplant type (p = 0.005) but with rejection only in DDLT (p = 0.0001). On multivariate analysis, DSA was an independent risk factor for graft failure regardless of liver transplant type (p = 0.017, preformed; p = 0.002, de novo ). In conclusion, although similar in prevalence, DSA may have more impact in DDLT than LDLT recipients. Although our findings need further validation, future research should more robustly test the effect of donor type and strategies to mitigate the impact of DSA. Abstract : This analysis of serum samples from the Adult to Adult Living Donor Liver Transplantation Cohort Study finds donor‐specific antibodies are an overall independent risk factor for graft failure and preliminarily appear more detrimental in deceased donor liver recipients compared to living donor liver recipients.